Real-world clinical outcomes of apalutamide versus abiraterone with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer
Apalutamide demonstrated deeper and more sustained PSA reductions, translating into delayed disease progression compared to abiraterone. Both treatments were generally well tolerated, though adverse events were more prevalent with apalutamide.
Authors
- Alberto Espuny-Miró
- Eduardo Pons-Fuster (ORCID: https://orcid.org/0000-0001-9595-5982)
- Juan José Fernández-Ávila
- Silverio Ros (ORCID: https://orcid.org/0009-0008-8616-2401)
- Celia Maria Gonzalez-Ponce
- María Sacramento Díaz-Carrasco (ORCID: https://orcid.org/0000-0002-9903-6665)
Institutions
- Hospital Universitario Virgen de la Arrixaca (ES)
Publication Details
- Journal
- International Journal of Clinical Pharmacy
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1007/s11096-025-01920-4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universidad de Murcia